March 22, 2022 02:00 PM EDTUpdated March 25, 11:50 AM

As branded drug sales surge, analysts predict China market will remain 'very attractive'

Nicole DeFeudis

Editor

The China market has long been considered a “large and untapped opportunity” for drugmakers — and according to Jefferies analysts, the former remains true.

In a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As branded drug sales surge, analysts predict China market will remain 'very attractive'

Nicole DeFeudis

Editor

Sign up to read this article for free.

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

As brand­ed drug sales surge, an­a­lysts pre­dict Chi­na mar­ket will re­main 'very at­trac­tive'

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

As branded drug sales surge, analysts predict China market will remain 'very attractive'

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M